Before the COVID-19 lockdowns and social distancing measures put face-to-face business routines and conference attendance on hold, Carlo Rivis was a regular on the investor meeting circuit, building up awareness of the mathematical modeling technologies that he says will one day be a viable alternative to traditional clinical trials.
Carlo Rivis: Know Your Own Value In Bringing Disruptive Innovation To Market
The Innovation Discovery CEO Has Made It His Role To Connect All The Dots In Delivering Novel Technology
Entrepreneur Carlo Rivis, one of In Vivo’s Rising Leaders, brought his disruptive innovation approaches to in-silico trials and digital avatar developer Computational Life, and now he is doing the same at Innovation Discovery.
More from Leadership
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.